UNSPSC 51392604: Cafedrine hydrochloride

This classification denotes a cns stimulant with the molecular formula C18H23N5O3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0N3M64B9R. European Medicines Agency schedules cafedrine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00934MIG. The term cafedrine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cafedrine hydrochloride under HS 29395900 and SITC 54145.

As of Q4 2014, CAFEDRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[C@@H]([C@@H](C1CCCCC1)O)NCCN2CNC3C2C(=O)N(C(=O)N3C)C.CL.

UNSPSC 51392604 Cafedrine hydrochloride is a Commodity code that shows minimal alignment between its abstract pharmaceutical name and the state and local solicitations currently posted under it. The recent opportunities tagged to this code do not reflect procurement of cafedrine hydrochloride specifically; instead, they capture broader pharmaceutical and health-service acquisitions that fall outside the commodity's stated scope. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems—a public-health intervention product unrelated to cafedrine—while the Texas Health and Human Services Commission issued an RFI for direct-to-manufacturer prescription program capabilities, which addresses pharmacy benefit management strategy rather than a specific pharmaceutical commodity. The issuing bodies represent county-level public health procurement and state-level benefits administration, but neither reflects demand for the commodity as named.

The code shows recent activity in Florida and Texas, but the opportunities present do not support a reliable characterization of cafedrine hydrochloride procurement in state and local markets. Seminole County's naloxone IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units annually with quarterly deliveries, and the Texas HHS RFI (HHS0017013, posted April 3, 2026) explored direct pharmaceutical contracting models. Neither opportunity targets cafedrine as a line item or procurement category. The code exhibits a mismatch between its nominal scope and actual recent solicitation activity, suggesting either a tagging error in the source data or dormant demand for this specific pharmaceutical in state and local procurement channels. Firms pursuing this code should verify that their products and capabilities align with the actual work being solicited under it rather than relying on the commodity name alone.